Earnings Call · Q1 FY2026·2026-05-13

Q1 26EPS +18.18%·Rev n/aQ4 25EPS -46.42%·Rev n/aQ3 25EPS +26.67%·Rev n/aQ2 25EPS -33.33%·Rev n/a⚠ consensus missing

Humacyte, Inc. HUMA

Thomas Johnson — IR Representative

Laura Niklason — President, CEO and Director

Dale Sander — CFO and Chief Corp. Deve. Off.

−19.4%1d on move date−19.2% vs SPY3d−19.8%5d−22.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more HUMA calls or request research access.

More HUMA calls Browse calls Request research access